M. Bromley

Aspergillus-mediated allergic airway inflammation is triggered by dendritic cell recognition of a defined spore morphotype, a process that can be targeted via antifungal therapeutics.

This study identifies a specific stage of Aspergillus fumigatus spore development that activates dendritic cells to trigger allergic airway inflammation and shows antifungal drugs can reduce this process.

The sulfur-related metabolic status of Aspergillus fumigatus during infection reveals cytosolic serine hydroxymethyltransferase as a promising antifungal target.

The paper identifies genes involved in sulfur metabolism in Aspergillus fumigatus during infection, highlighting ShmB as a promising antifungal target due to its essential role in virulence and structural differences from the human enzyme.

Aspergillus fumigatus can display persistence to the fungicidal drug voriconazole

This study shows that some Aspergillus fumigatus isolates can persist in the presence of voriconazole, a fungicidal drug, and this persistence is associated with a distinct transcriptional profile and reduced treatment efficacy.

Exploring a novel genomic safe-haven site in the human pathogenic mould Aspergillus fumigatus.

The paper identifies a conserved genomic safe-haven locus in Aspergillus fumigatus for inserting genetic constructs without affecting phenotype.

Weak Acid Resistance A (WarA), a novel transcription factor required for regulation of weak-acid resistance and spore-spore heterogeneity in Aspergillus niger

This study identifies WarA, a transcription factor in Aspergillus niger, and its role in weak acid resistance and heteroresistance, revealing new mechanisms for fungal survival in food preservatives.